D.E. Shaw & Co
JNCE

D.E. Shaw & Co’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

D.E. Shaw & Co’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-52,462
Closed -$159K – 5694
2022
Q2 		$159K Buy
+52,462
New +$255K ﹤0.01% 4616
2022
Q1 		– Sell
-68,776
Closed -$574K – 6145
2021
Q4 		$574K Buy
68,776
+34,388
+100% +$283K ﹤0.01% 4328
2021
Q3 		$256K Sell
34,388
-44,535
-56% -$276K ﹤0.01% 4448
2021
Q2 		$537K Buy
+78,923
New +$656K ﹤0.01% 4005
2020
Q3 		– Sell
-24,367
Closed -$168K – 4274
2020
Q2 		$168K Buy
+24,367
New +$131K ﹤0.01% 3814
2020
Q1 		– Sell
-34,068
Closed -$298K – 4369
2019
Q4 		$298K Sell
34,068
-132,970
-80% -$719K ﹤0.01% 3630
2019
Q3 		$557K Buy
167,038
+33,595
+25% +$134K ﹤0.01% 3163
2019
Q2 		$660K Sell
133,443
-40,365
-23% -$214K ﹤0.01% 2926
2019
Q1 		$1.08M Buy
173,808
+80,032
+85% +$387K ﹤0.01% 2568
2018
Q4 		$316K Buy
93,776
+24,572
+36% +$115K ﹤0.01% 3318
2018
Q3 		$450K Buy
+69,204
New +$515K ﹤0.01% 3168
2018
Q2 		– Sell
-30,879
Closed -$690K – 3947
2018
Q1 		$690K Buy
+30,879
New +$685K ﹤0.01% 2731
2017
Q3 		– Sell
-19,323
Closed -$271K – 3663
2017
Q2 		$271K Sell
19,323
-917
-5% -$19.6K ﹤0.01% 3068
2017
Q1 		$445K Buy
+20,240
New +$429K ﹤0.01% 2784

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

D.E. Shaw & Co's JNCE Position: Q3 2022 in Review

D.E. Shaw & Co sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2022, closing a stake of 52,462 shares — an estimated $159K sold.

D.E. Shaw & Co first reported a position in JNCE in Q1 2017 and held it in 14 quarters. The position peaked at $1.08M in Q1 2019. 102 funds tracked by Wall St. Rank hold JNCE as of Q3 2022.

  • D.E. Shaw & Co reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 52,462 Jounce Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $159K.
  • D.E. Shaw & Co first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 14 quarters.
  • D.E. Shaw & Co's Jounce Therapeutics, Inc. Common Stock position peaked at $1.08M in Q1 2019.
  • 102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.